David Nigel Hurst

Title: The Innovative Contributions of David Nigel Hurst

Introduction

David Nigel Hurst, based in Welwyn, GB, is a prolific inventor recognized for his significant contributions to pharmaceutical research and development. With a total of 11 patents to his name, Hurst has made valuable advancements in the field, particularly in treatments for inflammatory diseases.

Latest Patents

Among his latest innovations, Hurst's work on pyridazine derivatives stands out. This patent focuses on compounds that act as RORc modulators, along with methods for making these compounds and their usage in treating inflammatory diseases, such as arthritis. Another notable patent features oxadiazole derivatives that are active on sphingosine-1-phosphate (S1P). This invention encompasses novel compounds with pharmacological activity, processes for preparation, and pharmaceutical compositions for various disorders.

Career Highlights

Hurst's extensive career includes significant positions at prominent companies such as Hoffmann-La Roche Inc. and Glaxo Group Limited. His role in these organizations has been pivotal in driving innovative research and leading projects that have the potential to transform therapeutic options available for patients.

Collaborations

Collaboration has been a key element of Hurst's success. He has worked closely with esteemed colleagues, including Philip Stephen Jones and Paul Brittain Kay, sharing expertise and insights that further enhance the impact of their collective research efforts.

Conclusion

David Nigel Hurst's innovative work and dedication to pharmaceutical sciences demonstrate the importance of research and development in improving health outcomes. His patents not only reflect his ingenuity but also contribute significantly to the ongoing advancements in medicine, offering hope for effective treatments against various inflammatory conditions.